Measuring Acute Drug Demand in Humans

Summary

This research is being done to evaluate whether suvorexant may reduce the use of, subjective liking, and demand for various drugs.

Conditions

• Opioid Use Disorder
• Opioid Dependence

Interventions

DRUG

Drug A (Blinded Drug)

Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).

DRUG

Drug B (Blinded Drug)

Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).

DRUG

Drug C (Blinded Drug)

Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).

DRUG

Drug D (Blinded Drug)

Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).

DRUG

Suvorexant (20mg/day)

Double blind administration of suvorexant once per day during residential stay until discharge.

DRUG

Placebo

Double blind administration of placebo once per day during residential stay until discharge.

Sponsors & Collaborators

• National Institute on Drug Abuse (NIDA)

  collaborator NIH

• University of Maryland, Baltimore

  lead OTHER

Principal Investigators

• Justin Strickland, PhD · University of Maryland, Baltimore

Study Design

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

TRIPLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

65 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2023-08-08

Primary Completion

2027-10-31

Completion

2027-10-31

FDA Drug

Yes

Countries

• United States

Study Locations